A. Estimated creatinine clearance (eCrCl) ≥60 mL/min B. Three negative HIV tests performed at 2-month intervals over the prior 6 months C. Negative pregnancy test D. Negative serologic test for chronic hepatitis B virus (HBV) infection

A. Tenofovir disoproxil fumarate (TDF) B. TDF + lamivudine (3TC) C. TDF + emtricitabine (FTC) D. Tenofovir alafenamide (TAF) + emtricitabine (FTC) E. Both TDF/FTC and TAF/FTC

A. Test for HIV and hepatitis B virus infection every 3 months B. Test for HIV infection every 6 months and other sexually transmitted infections (STIs) every 6 months if the patient is symptomatic C. Test for HIV every 3 months and recalculate eCrCl every 6 months D. Assess for PrEP adherence and risk reduction at least once every 6 months

A. Fill the PEP prescription and advise the patient that he is a candidate for transitioning to PrEP immediately after completing his current 1-month course of PEP B. Fill the prescription and advise the patient that transitioning to PrEP requires a 1-month gap between completion of PEP and initiation of PrEP C. Immediately substitute PrEP for PEP and provide behavioral risk-reduction counseling D. Advise the patient that transitioning from PEP to once-daily PrEP eliminates the need for most behavioral risk-reduction strategies